Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT04297085
Recruiting Not applicable

Prospective Cohort Study on the Determinants of Venous THromboembolic Recurrence

NCT04297085 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Brest
Phase
Not applicable
Started
2020-05-28
Last updated
2026-06-15

Condition(s) studied

Thromboembolic Venous Disease

Investigational drug(s) / intervention(s)

Biologic sample

Biologic sample: Biological samples will be taken from the subjects included

Study summary

The main objective of the BREIZH-Cohorte study is to determine the incidence of recurrent short, medium and long-term thromboembolic venous disease as well as risk factors for recurrence in two specific populations: patients under 50 years of age, men and women (5 year recurrence), as well as cancer patients (all ages) (1 year recurrence).

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Subject aged 18 or over, or a minor with the consent of the parents and the minor, presenting with a thromboembolic venous disease * 50 and under or any age if active cancer * Affiliated to social security * Accepting to participate in the study. Exclusion Criteria: * Inability to communicate (comprehension disorder). * Refusal to participate.

Primary outcome measure(s)

  • Recurrence of thromboembolic venous disease — 20 years
    Recurrence of thromboembolic venous disease will be established at the end of patient monitoring

Trial sites (4)

FacilityCityRegionStatus
CHRU Brest Brest France Recruiting
HIA Clermont Tonnerre Brest Brest France Recruiting
CH Morlaix Morlaix France Recruiting
CH de Cornouaille Quimper France Recruiting

More University Hospital, Brest trials in France

Study on the Priorities of Patients Admitted to Intensive Care Starting soon
Children, Adolescents and Young Adults with Myeloproliferative Neoplasia: Study of Clinico-biological Characteristics and Complications (VYP) Recruiting
Interest of Cryotherapy in Reducing Pain During Radial Arterial Blood Sampling Starting soon
Study of Alloknesia in Atopic Dermatitis Recruiting
Validation of a Method of Screening for Sleep Disorders in Children With Cerebral Palsy, Using Connected Tools Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04297085 on ClinicalTrials.gov ↗ ← All trials in France